Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer : a multicenter study

• Uchida, Toyoaki

  The Department of Urology, Tokai University Hachioji Hospital

• Baba, Shiro

  The Department of Urology, Kitasato University

• Irie, Akira

  The Department of Urology, Sapporo Medical University

• Soh, Shigehiro

  The Department of Urology, Asahi General Hospital

• Masumori, Naoya

  The Department of Urology, National Cancer Center

• Tsukamoto, Taiji

  The Department of Urology, Chiba University

• Nakatsu, Hiroomi

  The Department of Urology, Tokyo University

• Fujimoto, Hiroyuki

  The Department of Urology, National Defense Medical College

• Kakizoe, Tadao

  The Department of Urology, Tokyo Medical University

• Ueda, Takeshi

  The Department of Urology, Kanazawa Medical University

• Ichikawa, Tomohiko

  The Department of Urology, Hamamatsu University School of Medicine

• Ohta, Nobutaka

  The Department of Urology, Nara Medical University

• Kitamura, Tadaichi

  The Department of Urology, Okayama University

• Sumitomo, Makoto

  The Department of Urology, Kumamoto University

• Hayakawa, Masamichi

  The Department of Urology, Kyusyu University

• Aoyagi, Teiichiro

• Tachibana, Masaaki

• Ikeda, Ryusuke

• Suzuki, Kohji

• Tsuru, Nobuo

• Suzuki, Kazuo

• Ozono, Seiichiro

• Fujimoto, Kiyohide

• Hirao, Yoshihiko

• Monden, Kohichi

• Nasu, Yasutomo

• Kumon, Hiromi

• Nishi, Kazuhiko

• Ueda, Shoichi

• Koga, Hirofumi

• Naitoh, Seiji

Bibliographic Information

Other Title

• 限局性前立腺癌に対する高密度焦点式超音波療法:多施設共同研究

Abstract

We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage T1c-2NOM0 prostate cancer were treated using the Sonablate 500TM HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78% and 76%, respectively. Biochemical disease-free survival rates in patients with stage T1c, T2a and T2b groups at 2 years were 89, 67% and 40% (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72% and 80% (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75% and 78% (p = 0.6152). No viable tumor cells were noted in 68% of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p < 0.01). No statistically significant differences were noted in International Prostate Symptom Score, maximum urinary flow rate and quality of life analysis with Functional Assessment of Cancer Therapy. HIFU therapy appears to be minimally invasive, efficacious and safe for patients with localized prostate cancer with pretreatment PSA levels less than 20 ng/ml.

Journal

• Hinyokika Kiyo

  Hinyokika Kiyo 51 (10), 651-658, 2005-10

  泌尿器科紀要刊行会

Keywords

• Prostate cancer
• High-intensity focused ultrasound
• Minimally invasive surgery

Details

• CRID: 1050282677276970496
• NII Article ID: 120002141521
• NII Book ID: AN00208315
• ISSN: 00181994
• HANDLE: 2433/113709
• NDL BIB ID: 7713059
• Web Site: http://id.ndl.go.jp/bib/7713059
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7713059
• Web Site: https://search.jamas.or.jp/link/ui/2006115865
• Text Lang: en
• Article Type: departmental bulletin paper
• Data Source:
  • IRDB
  • NDL
  • CiNii Articles
  • KAKEN